9-β-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells

Molecular Pharmacology

Volumn 66, Issue 1, 2004, Pages 178-186

  Fang, Jing ^a   Cao, Zongxian ^a   Chen, Yi Charlie ^b   Reed, Eddie ^a   Jiang, Bing Hua ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b Alderson Broaddus College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEOTIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE OVEREXPRESSION; GROWTH INHIBITION; GROWTH REGULATION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTORS; VIDARABINE;

EID: 3042582142     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.1.178     Document Type: Article

References (39)

1. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, and Brown LF (1996) Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Investig 74:1105-1115.
2. Adkins JC, Peters DH, and Markham A (1997) Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005-1037.
3. Akmed NN, Grimes HL, Bellacosa A, Chan TO, and Tsichlis PN (1997) Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 94:3627-3632.
4. Arsham AM, Plas DR, Thompson CB, and Simon MC (2002) Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilizatian of HIF-1α nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277:15162-15170.
5. Bamberger ES and Perrett CW (2002) Angiogenesis in epithelian ovarian cancer. Mol Pathol 55:348-359.
6. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55:678-684.
7. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, and Jaffe RB (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721-5728.
8. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature (Lond) 407:249-257.
9. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803.
10. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18.
11. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613.
12. Foster K, Osborne RJ, Huddart RA, Affara NA, Ferguson-Smith MA, and Maher ER (1995) Molecular genetic analysis of the Von Hippel-Lindau Disease (VHL) tumour suppressor gene in gonadal tumours. Eur J Cancer 31A:2392-2395.
13. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-38211.
14. Gao N, Ding M, Zheng JZ, Zhang Z, Leonard SS, Liu KJ, Shi X, and Jiang BH (2002) Vanadate-induced expression of hypoxia-inducible factor 1α and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 277:31963-31971.
15. Huang P and Plunkett W (1995) Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188.
16. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, and Abraham RT (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014.
17. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science (Wash DC) 292:464-468.
18. 2-regulated prolyl hydroxylation. Science (Wash DC) 292:468-472.
19. Jiang BH, Agani F, Passaniti A, and Semenza GL (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328-5335.
20. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, and Vogt PK (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12:363-369.
21. Jiang BH, Zheng JZ, Aoki M, and Vogt PK (2000) Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97:1749-1753.
22. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, and Poellinger L (1999) Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 274:6519-6525.
23. Knowles HJ, Raval RR, Harris AL, and Ratcliffe PJ (2003) Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63:1764-1768.
24. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, and Gill PS (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913.
25. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond) 399:271-275.
26. Mazure NM, Chen EY, Yeh P, Laderoute KR, and Giaccia AJ (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 58:3436-3440.
27. Mesiano S, Ferrara N, and Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249-1256.
28. Olson TA, Mohanraj D, Carson LF, and Ramakrishnan S (1994) Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280.
29. Page EL, Robitaille GA, Pouyssegur J, and Richard DE (2002) Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J Biol Chem 277:48403-48409.
30. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, and Bedi A (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14:34-44.
31. Richard DE, Berra E, Gothie E, Roux D, and Pouyssegur J (1999) P42/P44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 274:32631-32637.
32. Salceda S and Caro J (1997) Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642-22647.
33. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
34. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, and Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102.
35. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, and Fidler IJ (2000) Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16:445-454.
36. Yaginuma Y and Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52:4196-4199.
37. Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, et al. (2003) The oncegene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 63:4225-4231.
38. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, and Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/ AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545.
39. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396.